Findings from a phase I/IIa study indicate that combining the investigational indoleamine 2,3-dioxygenase 1 inhibitor BMS-986205 with nivolumab is safe and boosts response rates among patients with bladder and cervical cancers.

中文翻译：

---

阻止IDO1有助于收缩膀胱，宫颈肿瘤

I / IIa期研究的结果表明，将吲哚胺2,3-二加氧酶1抑制剂BMS-986205与nivolumab组合使用是安全的，可提高膀胱癌和宫颈癌患者的反应率。